Memiontec Secures its Largest Contract to date following Award of a New S$56.6 Million Contract by PUB
Singapore, Mar 25, 2022 – (ACN Newswire) – Memiontec Holdings Ltd. (“Memiontec” or the “Company”,…
Singapore, Mar 25, 2022 – (ACN Newswire) – Memiontec Holdings Ltd. (“Memiontec” or the “Company”,…
UserTesting helps companies innovate new ways to engage with customers as digital transformation continues to…
Customers will continue to be served through their respective Citizens and Investors branches, websites and…
Personalis’ oncology diagnostics business expected to build on foundation of advanced technology already the driver…
FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (NASDAQ: STAB) (the…
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of…
— Proposal of one-tier board structure & appointment of three new directors — Mechelen, Belgium;…
Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs Partnership Activity…
TORONTO, March 24, 2022 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX – XLY) (OTCQX:…
WINNIPEG, Manitoba, March 24, 2022 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the…
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Imago BioSciences, Inc. (“Imago”) (Nasdaq:…
– Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC)…
BILLERICA, Mass., March 24, 2022 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ:…
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ:…
On track to report topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22…
MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing…
Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi) Initial…
– Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from…
Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year…
Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing…